-+ 0.00%
-+ 0.00%
-+ 0.00%

Lipocine Completes Scheduled Independent Data Safety Monitoring Board Review Of Phase 3 Trial Of LPCN 1154 In Postpartum Depression

Benzinga·11/18/2025 13:11:26
Listen to the news
  • Per the Drug Safety Monitoring Board (DSMB) meeting evaluating one-third of planned participants, study to continue as planned
  • More than half of planned participants have completed dosing with no dose reductions, discontinuations, drug-related SAEs, loss of consciousness, or excessive sedation reported
    • Topline results are on track for the second quarter of 2026